Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
Corporate Deck January 2021
JPM Presentation Jan 14, 2021
Investor Deck December 2020
Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020
Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
Corporate Deck September 2020
Corporate Deck August 2020
Press Releases
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
press release
January 11, 2021
– European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021 – Phase 3 EDELWEISS…
Read moreObsEva SA to Participate in JP Morgan Virtual Healthcare Conference January 11 – 14, 2021
press release
January 7, 2021
Geneva, Switzerland and Boston, MA – January 7, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…
Read moreObsEva appoints David Renas as Chief Financial Officer
press release
January 4, 2021
Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2020
June 9, 2020
ObsEva Annual General Meeting 2019
May 8, 2019
Upcoming Events
ObsEva SA to Participate in JP Morgan Virtual Healthcare Conference January 11 – 14, 2021
Event
January 31, 2021
Stock Information
Latest Press Release
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
– European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021 – Phase 3 EDELWEISS…
Read moreInvestor Contact
Media Contact
Media Switzerland & Europe
Shauna Dillon
+41 (0)22 552 1550 Office
+41 79 360 3533 Mobile
Media United States
Shauna Dillon
+41 (0)22 552 1550 Office
+41 (0)79 360 3533 Mobile
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Media Switzerland & Europe
Shauna Dillon
+41 (0)22 552 1550 Office
+41 79 360 3533 Mobile
Media United States
Shauna Dillon
+41 (0)22 552 1550 Office
+41 (0)79 360 3533 Mobile
Sign up for news
